1. Molecular Imaging of Radiolabeled Bispecific T-cell Engager 89Zr-AMG211 Targeting CEA-positive Tumors

    Waaijer, S. J. H., Warnders, F-J., Stienen, S. K., Friedrich, M., Sternjak, A., Cheung, H-K., Terwisscha van Scheltinga, A. G. T., Schröder, C. P., de Vries, E. G. & Lub-de Hooge, M. N. 6-Jul-2018 In : Clinical Cancer Research.

    Research output: Contribution to journalArticle

  2. Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: A Gestalt approach?' by Del Paggio

    Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J. -Y., Tabernero, J., Zielinski, C., Piccart, M. J. & de Vries, E. G. E. Feb-2018 In : Annals of Oncology. 29, 2, p. 521-522 3 p.

    Research output: Contribution to journalLetter

  3. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: A guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group

    Camidge, D. R., Lee, E. Q., Lin, N. U., Margolin, K., Ahluwalia, M. S., Bendszus, M., Chang, S. M., Dancey, J., de Vries, E. G. E., Harris, G. J., Hodi, F. S., Lassman, A. B., Macdonald, D. R., Peereboom, D. M., Schiff, D., Soffietti, R., van den Bent, M. J., Wefel, J. S. & Wen, P. Y. Jan-2018 In : Lancet Oncology. 19, 1, p. E20-E32 13 p.

    Research output: Contribution to journalReview article

View all (1,020) »

View graph of relations

ID: 162081